168 related articles for article (PubMed ID: 28407688)
1. NPC-26 kills human colorectal cancer cells via activating AMPK signaling.
Zhao Z; Feng L; Wang J; Cheng D; Liu M; Ling M; Xu W; Sun K
Oncotarget; 2017 Mar; 8(11):18312-18321. PubMed ID: 28407688
[TBL] [Abstract][Full Text] [Related]
2. Aqueous Oldenlandia diffusa extracts inhibits colorectal cancer cells via activating AMP-activated protein kinase signalings.
Lu PH; Chen MB; Ji C; Li WT; Wei MX; Wu MH
Oncotarget; 2016 Jul; 7(29):45889-45900. PubMed ID: 27322552
[TBL] [Abstract][Full Text] [Related]
3. Icaritin activates JNK-dependent mPTP necrosis pathway in colorectal cancer cells.
Zhou C; Chen Z; Lu X; Wu H; Yang Q; Xu D
Tumour Biol; 2016 Mar; 37(3):3135-44. PubMed ID: 26427664
[TBL] [Abstract][Full Text] [Related]
4. AMPK-autophagy inhibition sensitizes icaritin-induced anti-colorectal cancer cell activity.
Zhou C; Gu J; Zhang G; Dong D; Yang Q; Chen MB; Xu D
Oncotarget; 2017 Feb; 8(9):14736-14747. PubMed ID: 28103582
[TBL] [Abstract][Full Text] [Related]
5. Erastin Disrupts Mitochondrial Permeability Transition Pore (mPTP) and Induces Apoptotic Death of Colorectal Cancer Cells.
Huo H; Zhou Z; Qin J; Liu W; Wang B; Gu Y
PLoS One; 2016; 11(5):e0154605. PubMed ID: 27171435
[TBL] [Abstract][Full Text] [Related]
6. The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo.
Dong YY; Zhuang YH; Cai WJ; Liu Y; Zou WB
Tumour Biol; 2016 Nov; 37(11):15053-15063. PubMed ID: 27658776
[TBL] [Abstract][Full Text] [Related]
7. Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation.
Chen MB; Liu YY; Xing ZY; Zhang ZQ; Jiang Q; Lu PH; Cao C
Mol Cancer Ther; 2018 Jun; 17(6):1229-1239. PubMed ID: 29592879
[TBL] [Abstract][Full Text] [Related]
8. Activating AMP-activated protein kinase by an α1 selective activator compound 13 attenuates dexamethasone-induced osteoblast cell death.
Guo S; Mao L; Ji F; Wang S; Xie Y; Fei H; Wang XD
Biochem Biophys Res Commun; 2016 Mar; 471(4):545-52. PubMed ID: 26891866
[TBL] [Abstract][Full Text] [Related]
9. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of autophagy enhances synergistic effects of Salidroside and anti-tumor agents against colorectal cancer.
Li H; Chen C
BMC Complement Altern Med; 2017 Dec; 17(1):538. PubMed ID: 29246220
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
[TBL] [Abstract][Full Text] [Related]
12. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
[TBL] [Abstract][Full Text] [Related]
13. Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543.
Ju T; Gao D; Fang ZY
Biochem Biophys Res Commun; 2016 Feb; 470(3):728-734. PubMed ID: 26775841
[TBL] [Abstract][Full Text] [Related]
14. Targeting PP2A activates AMPK signaling to inhibit colorectal cancer cells.
Dai C; Zhang X; Xie D; Tang P; Li C; Zuo Y; Jiang B; Xue C
Oncotarget; 2017 Nov; 8(56):95810-95823. PubMed ID: 29221169
[TBL] [Abstract][Full Text] [Related]
15. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis.
Wang B; Wang XB; Chen LY; Huang L; Dong RZ
Biochem Biophys Res Commun; 2013 Jul; 437(1):1-6. PubMed ID: 23743198
[TBL] [Abstract][Full Text] [Related]
16. Activation of AMPK by chitosan oligosaccharide in intestinal epithelial cells: Mechanism of action and potential applications in intestinal disorders.
Muanprasat C; Wongkrasant P; Satitsri S; Moonwiriyakit A; Pongkorpsakol P; Mattaveewong T; Pichyangkura R; Chatsudthipong V
Biochem Pharmacol; 2015 Aug; 96(3):225-36. PubMed ID: 26047848
[TBL] [Abstract][Full Text] [Related]
17. AT7867 Inhibits Human Colorectal Cancer Cells via AKT-Dependent and AKT-Independent Mechanisms.
Zhang S; Deng Z; Yao C; Huang P; Zhang Y; Cao S; Li X
PLoS One; 2017; 12(1):e0169585. PubMed ID: 28081222
[TBL] [Abstract][Full Text] [Related]
18. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
Min H; Xu M; Chen ZR; Zhou JD; Huang M; Zheng K; Zou XP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):167-76. PubMed ID: 24842158
[TBL] [Abstract][Full Text] [Related]
20. Preclinical study of cinobufagin as a promising anti-colorectal cancer agent.
Lu XS; Qiao YB; Li Y; Yang B; Chen MB; Xing CG
Oncotarget; 2017 Jan; 8(1):988-998. PubMed ID: 27894091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
